The coexpression of SUMO family members and a variety of cancer-promoting immune checkpoint genes and the positive correlation between SUMO4 expression level and sensitivity to various targeted or chemotherapeutic drugs, including gemcitabine, paclitaxel, and doxorubicin, indicate the potential translational value of this study. The gene discussed is SUMO4; the disease is cancer.